Want to see OMER full AI Analyst Report?
OMER Stock Chart & Stats
$13.44
-$0.23(-2.31%)
At close: 4:00 PM EST
$13.44
-$0.23(-2.31%)
Day’s Range― - ―
52-Week Range$3.44 - $17.65
Previous CloseN/A
Volume193.12K
Average Volume (3M)1.99M
Market Cap
$712.17M
Enterprise Value$934.76
Total Cash (Recent Filing)$135.32M
Total Debt (Recent Filing)$310.63M
Price to Earnings (P/E)7.9
Beta1.31
Next Earnings
Aug 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.30
Shares Outstanding72,375,360
10 Day Avg. Volume1,266,357
30 Day Avg. Volume1,985,436
Financial Highlights & Ratios
PEG Ratio3.32
Price to Book (P/B)-9.00
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$33.00Price Target Upside145.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.05
Revenue Forecast (FY)$67.84M
Bulls Say, Bears Say
Bulls Say
First-to-market Approval & LaunchBeing the first and only approved MASP-2 inhibitor for TA-TMA establishes a durable commercial beachhead. First-mover status supports formulary placement, clinical adoption in a rare indication, and provides leverage for label expansion and international rollouts, sustaining long-term revenues.
Substantial Non-dilutive Partnership FundingThe Novo Nordisk transaction delivers meaningful non-dilutive capital and milestone upside, materially extending runway and reducing immediate financing risk. This funding supports commercialization, R&D, and frees management to prioritize strategic programs without short-term equity dilution.
Improved Liquidity And Lower Debt BurdenA sizable cash balance alongside dramatic debt reduction materially improves financial flexibility and reduces interest and covenant pressure. This stronger capital structure supports commercial scale-up and pipeline investment, lowering default and refinancing risk over the medium term.
Bears Say
Sustained Cash Burn And Negative Cash FlowSignificant negative operating and free cash flow indicates the business is not yet self-sustaining; continued R&D and commercialization will require ongoing cash. Unless product revenues ramp as planned, the company may need additional financing, which could dilute shareholders or increase leverage.
Negative Shareholders' EquityNegative equity reflects cumulative losses and a weakened capital base, constraining borrowing capacity and strategic optionality. This structural balance-sheet weakness increases vulnerability to shocks, may elevate financing costs, and limits the company's ability to absorb setbacks during commercialization.
Early Adoption Uncertainty And Gross-to-net PressureThe early customer base is small with limited patient-level disclosure, creating uncertainty about sustained uptake. Concurrently, gross-to-net adjustments and potential 340B impacts can structurally reduce realized net revenue per unit, pressuring margins and cash conversion as scale is pursued.
Omeros News
OMER FAQ
What was Omeros Corporation’s price range in the past 12 months?
Omeros Corporation lowest stock price was $3.44 and its highest was $17.65 in the past 12 months.
What is Omeros Corporation’s market cap?
Omeros Corporation’s market cap is $712.17M.
When is Omeros Corporation’s upcoming earnings report date?
Omeros Corporation’s upcoming earnings report date is Aug 12, 2026 which is in 19 days.
How were Omeros Corporation’s earnings last quarter?
Currently, no data Available
Is Omeros Corporation overvalued?
According to Wall Street analysts Omeros Corporation’s price is currently Undervalued.
Does Omeros Corporation pay dividends?
Omeros Corporation does not currently pay dividends.
What is Omeros Corporation’s EPS estimate?
Omeros Corporation’s EPS estimate is -0.27.
How many shares outstanding does Omeros Corporation have?
Omeros Corporation has 72,375,360 shares outstanding.
What happened to Omeros Corporation’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Omeros Corporation?
Currently, no hedge funds are holding shares in OMER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.00 (145.54% Upside)
$33.00 (145.54% Upside)
Blogger Sentiment
Neutral
OMER Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 13.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
163.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.69%
Trailing 12-Months
Company Description
Omeros Corporation
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
OMER Stock 12 Month Forecast
Average Price Target
$33.00
▲(145.54% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.73% Insiders
7.87% Mutual Funds
0.04% Other Institutional Investors
74.57% Public Companies and
Individual Investors